Goldman Sachs’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.57M | Sell |
348,208
-7,904
| -2% | -$35.6K | ﹤0.01% | 3566 |
|
|
2025
Q1 | $1.65M | Buy |
356,112
+196,238
| +123% | +$911K | ﹤0.01% | 3490 |
|
|
2024
Q4 | $1.11M | Sell |
159,874
-18,731
| -10% | -$130K | ﹤0.01% | 3857 |
|
|
2024
Q3 | $947K | Buy |
178,605
+86,256
| +93% | +$457K | ﹤0.01% | 3783 |
|
|
2024
Q2 | $345K | Buy |
92,349
+76,585
| +486% | +$286K | ﹤0.01% | 4134 |
|
|
2024
Q1 | $111K | Sell |
15,764
-21,414
| -58% | -$151K | ﹤0.01% | 4448 |
|
|
2023
Q4 | $210K | Sell |
37,178
-17,032
| -31% | -$96.2K | ﹤0.01% | 4307 |
|
|
2023
Q3 | $260K | Buy |
54,210
+8,874
| +20% | +$42.5K | ﹤0.01% | 4170 |
|
|
2023
Q2 | $311K | Buy |
45,336
+13,103
| +41% | +$89.8K | ﹤0.01% | 4211 |
|
|
2023
Q1 | $251K | Sell |
32,233
-11,729
| -27% | -$91.4K | ﹤0.01% | 4425 |
|
|
2022
Q4 | $335K | Buy |
43,962
+10,668
| +32% | +$81.2K | ﹤0.01% | 4296 |
|
|
2022
Q3 | $272K | Sell |
33,294
-6,822
| -17% | -$55.7K | ﹤0.01% | 4587 |
|
|
2022
Q2 | $388K | Sell |
40,116
-9,701
| -19% | -$93.8K | ﹤0.01% | 4546 |
|
|
2022
Q1 | $698K | Buy |
49,817
+15,071
| +43% | +$211K | ﹤0.01% | 4372 |
|
|
2021
Q4 | $710K | Buy |
34,746
+15,627
| +82% | +$319K | ﹤0.01% | 4273 |
|
|
2021
Q3 | $426K | Sell |
19,119
-89,381
| -82% | -$1.99M | ﹤0.01% | 4477 |
|
|
2021
Q2 | $2.46M | Buy |
+108,500
| New | +$2.46M | ﹤0.01% | 3349 |
|